Processing

Please wait...

Settings

Settings

1. WO2007029021 - 1,5-SUBSTITUTED TETRAZOLES AS THERAPEUTIC COMPOUNDS

Publication Number WO/2007/029021
Publication Date 15.03.2007
International Application No. PCT/GB2006/003346
International Filing Date 08.09.2006
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4168
having a nitrogen atom attached in position 2, e.g. clonidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
C07D 413/12 (2006.01)
C07D 417/04 (2006.01)
C07D 413/04 (2006.01)
C07D 417/12 (2006.01)
A61K 31/4168 (2006.01)
A61P 9/00 (2006.01)
CPC
C07D 257/04
C07D 403/04
C07D 413/04
C07D 413/12
C07D 417/04
C07D 417/12
Applicants
  • THE UNIVERSITY OF EDINBURGH [GB/GB]; Old College South Bridge Edinburgh Lothian EH8 9YL, GB (AllExceptUS)
  • WEBSTER, Scott, Peter [GB/GB]; GB (UsOnly)
  • SECKL, Jonathan, Robert [GB/GB]; GB (UsOnly)
  • WALKER, Brian, Robert [GB/GB]; GB (UsOnly)
  • WARD, Peter [GB/GB]; GB (UsOnly)
  • PALLIN, Thomas, David [GB/GB]; GB (UsOnly)
  • DYKE, Hazel, Joan [GB/GB]; GB (UsOnly)
Inventors
  • WEBSTER, Scott, Peter; GB
  • SECKL, Jonathan, Robert; GB
  • WALKER, Brian, Robert; GB
  • WARD, Peter; GB
  • PALLIN, Thomas, David; GB
  • DYKE, Hazel, Joan; GB
Agents
  • WYTENBURG, Wilhelmus ; Mewburn Ellis LLP York House 23 Kingsway London Greater London WC2B 6HP, GB
Priority Data
0518361.108.09.2005GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) 1,5-SUBSTITUTED TETRAZOLES AS THERAPEUTIC COMPOUNDS
(FR) TETRAZOLES 1,5-SUBSTITUÉS EN TANT QUE COMPOSÉS THÉRAPEUTIQUES
Abstract
(EN)
The present invention pertains to certain 1,5-substituted-1H-tetrazole compounds that, inter alia, inhibit 11&bgr;- hydroxysteroid dehydrogenase type 1 (11&bgr;-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11&bgr;-hydroxysteroid dehydrogenase type 1; to treat conditions that are ameliorated by the inhibition of 11&bgr;-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes conditions such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS conditions such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
(FR)
La présente invention concerne certains composés 1H-tétrazole 1,5 substitués qui, notamment, inhibent la 11&bgr;-hydroxystéroïde déshydrogénase de type 1(11&bgr;-HSD1). Cette invention concerne également des compositions pharmaceutiques comprenant ces composés et l’utilisation de ces composés et compositions, tant in vitro qu’in vivo, afin d’inhiber la 11&bgr;-hydroxystéroïde déshydrogénase de type 1; afin de traiter des pathologies atténuées par l’inhibition de la 11&bgr;-hydroxystéroïde déshydrogénase de type 1; afin de traiter le syndrome métabolique, qui inclut des affections telles que le diabète de type 2 et l’obésité, ainsi que des pathologies associées, notamment l'insulinorésistance, l’hypertension, les troubles lipidiques et les pathologies cardiovasculaires telles que les maladies cardiaques ischémiques (coronariennes) ; afin de traiter des affections du SNC telles que le déficit cognitif léger et la démence précoce, y compris la maladie d’Alzheimer; etc.
Also published as
EP06779363
EP6779363
Latest bibliographic data on file with the International Bureau